AIMS: Genetic variability within the SLCO1B1 and ABCB1 transporter genes has been associated with modification of statin effectiveness in cholesterol management. MATERIALS & METHODS: We conducted a case-control study using a population-based registry of pharmacy records linked to the hospital discharge records. Within a hypercholesterolemic cohort, we included 668 myocardial infarction cases and 1217 controls. RESULTS: We tested 24 tagging SNPs and found two SNPs within ABCB1 (rs3789244, p = 0.01; rs1922242, p = 0.01) to interact with statin treatment. In addition, we found a nonsignificant haplotype-treatment interaction (p = 0.054). The odds ratio for subjects homozygous for SLCO1B1*1A was 0.49 (95% CI: 0.34-0.71) compared with 0.31 (95% CI: 0.24-0.41) for heterozygous or noncarriers of the *1A allele. CONCLUSION: This is the first study to demonstrate that common genetic variability within the SLCO1B1 and ABCB1 genes is associated with the modification of the effectiveness of statins in the prevention of the clinical outcome, myocardial infarction.
AIMS: Genetic variability within the SLCO1B1 and ABCB1 transporter genes has been associated with modification of statin effectiveness in cholesterol management. MATERIALS & METHODS: We conducted a case-control study using a population-based registry of pharmacy records linked to the hospital discharge records. Within a hypercholesterolemic cohort, we included 668 myocardial infarction cases and 1217 controls. RESULTS: We tested 24 tagging SNPs and found two SNPs within ABCB1 (rs3789244, p = 0.01; rs1922242, p = 0.01) to interact with statin treatment. In addition, we found a nonsignificant haplotype-treatment interaction (p = 0.054). The odds ratio for subjects homozygous for SLCO1B1*1A was 0.49 (95% CI: 0.34-0.71) compared with 0.31 (95% CI: 0.24-0.41) for heterozygous or noncarriers of the *1A allele. CONCLUSION: This is the first study to demonstrate that common genetic variability within the SLCO1B1 and ABCB1 genes is associated with the modification of the effectiveness of statins in the prevention of the clinical outcome, myocardial infarction.
Authors: Bas J M Peters; Helmi Pett; Olaf H Klungel; Bruno H Ch Stricker; Bruce M Psaty; Nicole L Glazer; Kerri L Wiggins; Josh C Bis; Anthonius de Boer; Anke-Hilse Maitland-van der Zee Journal: Atherosclerosis Date: 2011-06-17 Impact factor: 5.162
Authors: F F Alharbi; P C Souverein; M C de Groot; A H Maitland-van der Zee; A de Boer; O H Klungel Journal: J Hum Hypertens Date: 2017-03-23 Impact factor: 3.012
Authors: Damiano Baldassarre; Mauro Amato; Beatrice Frigerio; Gualtiero Columbo; Philip F Binkley; Saurabh R Pandey; Adam M Suhy; Katherine Hartmann; Joseph P Kitzmiller Journal: G Ital Arterioscler Date: 2013-11
Authors: Josephine H Li; Sunil Suchindran; Svati H Shah; William E Kraus; Geoffrey S Ginsburg; Deepak Voora Journal: Pharmacogenomics Date: 2015 Impact factor: 2.533
Authors: Wai-Johnn Sam; Christine E Chamberlain; Su-Jun Lee; Joyce A Goldstein; Douglas A Hale; Roslyn B Mannon; Allan D Kirk; Yuen Yi Hon Journal: Transplantation Date: 2012-11-15 Impact factor: 4.939
Authors: Joseph P Kitzmiller; Philip F Binkley; Saurabh R Pandey; Adam M Suhy; Damiano Baldassarre; Katherine Hartmann Journal: Discov Med Date: 2013-08 Impact factor: 2.970